OncologyColorectal Neoplasms

GI Cancers Surge: Targeted Therapy Comes to CRC, Gastric, and Biliary Tract

ASCO 2026 was the year GI oncology arrived: four tumor types, simultaneous breakthroughs

SR-2026-016

EditorMara Voss

CopywritersEditorial Team

Coming Soon

GI Cancers Surge: Targeted Therapy Comes to CRC, Gastric, and Biliary Tract

ASCO 2026 was the year GI oncology arrived: four tumor types, simultaneous breakthroughs

Why We Are Covering This

GI cancers are collectively the deadliest cancer group, and 2025 delivered the first targeted KRAS approval in colorectal cancer alongside ADC and HER2-directed breakthroughs in gastric and biliary tract disease. ASCO 2026 flagged this as the GI cancer year.

What to Expect

You will leave with a biomarker testing cascade for each GI tumor type, a clear view of which agents are approved versus regulatory-ready, and an understanding of the CRO opportunity across GI cancer trials.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-01607/26

Solid Tumors

Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging

Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.

Prostatic Neoplasms

Prostate Care: Balancing Immediate Relief with Long-Term Retreatment

Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.

Breast Neoplasms

Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy

A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.

Breast Neoplasms

Giredestrant Improves Breast Cancer Survival Regardless of Menopause

Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.

GI Cancers Surge: Targeted Therapy Comes to CRC, Gastric, and Biliary Tract

GI Cancers Surge: Targeted Therapy Comes to CRC, Gastric, and Biliary Tract

Be first when this report publishes

Related Articles